Twist Bioscience CorpTWST

NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Price (close)
$184.03
Market cap
$11.5B
P/E
—
Revenue (TTM)
$431.8M
Net income
-$136.7M
Dividend yield
—
1-year total return
588.0%
Net margin
-31.7%
Revenue growth
19.2%
Debt / equity
—

What Twist Bioscience Corp does.

At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.

We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.8% the amount of chemicals we estimate would be used per gene as compared to plate-based synthesis. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost and quicker than our competitors.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$90.1M$132.3M$203.6M$245.1M$313.0M$376.6M
Net income-$139.9M-$152.1M-$217.9M-$204.6M-$208.7M-$77.7M
Free cash flow-$152.1M-$139.3M-$226.2M-$170.3M-$69.2M-$75.6M

More on TWST.

Figures from Twist Bioscience Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.